1. Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease.

    Inflammatory Bowel Diseases 22(7):1575 (2016) PMID 27271490

    Histamine is a key immunoregulatory mediator in immediate-type hypersensitivity reactions and chronic inflammatory responses, in particular histamine suppresses proinflammatory responses to bacterial ligands, through histamine receptor 2 (H2R). The aim of this study was to investigate the effect...
  2. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.

    Journal of Allergy and Clinical Immunology 138(1):162 (2016) PMID 27373329

    An immunotherapy formulation consisting of 3 contiguous overlapping peptides (COPs) derived from Bet v 1, the major birch pollen allergen, showed good clinical tolerability in a previous phase I/IIa clinical trial. We sought to evaluate the efficacy and safety of allergen-specific immunotherapy ...
  3. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

    Journal of Allergy and Clinical Immunology 137(5):1347 (2016) PMID 27155030

    In this consensus document we summarize the current knowledge on major asthma, rhinitis, and atopic dermatitis endotypes under the auspices of the PRACTALL collaboration platform. PRACTALL is an initiative of the European Academy of Allergy and Clinical Immunology and the American Academy of All...
  4. Allergen Immunotherapy: Past, Present, and Future.

    Allergy, Asthma & Immunology Research 8(3):191 (2016) PMID 26922928 PMCID PMC4773206

    Allergen-specific immunotherapy (AIT), although in clinical use for more than a century, is still the only causal treatment of allergic diseases. The safety and efficacy of AIT has been demonstrated in a large number of clinical trials. In addition to allergy symptom reduction AIT plays an essen...
  5. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics.

    Journal of Allergy and Clinical Immunology 137(2):358 (2016) PMID 26853128

    This article continues the comprehensive international consensus (ICON) statement on allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The conclusions below focus on key mechanisms of AIT-triggered tolerance, requirements in allergen standardization, AIT co...
  6. Sublingual immunotherapy (SLIT)--indications, mechanism, and efficacy: Position paper prepared by the Section of Immunotherapy, Polish Society of Allergy.

    Annals of Agricultural and Environmental Medicine 23(1):44 (2016) PMID 27012173

    SLIT (sublingual immunotherapy,) induces allergen-specific immune tolerance by sublingual administration of a gradually increasing dose of an allergen. The mechanism of SLIT is comparable to those during SCIT (subcutaneous immunotherapy), with the exception of local oral dendritic cells, pre-pro...
    PDF not found
  7. International consensus on allergy immunotherapy.

    Journal of Allergy and Clinical Immunology 136(3):556 (2015) PMID 26162571

    Allergen immunotherapy (AIT) has been used to treat allergic disease since the early 1900s. Despite numerous clinical trials and meta-analyses proving AIT efficacious, it remains underused and is estimated to be used in less than 10% of patients with allergic rhinitis or asthma worldwide. In add...
  8. T-cell regulation during viral and nonviral asthma exacerbations.

    Journal of Allergy and Clinical Immunology 136(1):194 (2015) PMID 25605274

    Immune mechanisms underlying acute episodes of asthma are poorly understood. The present study demonstrates by using multicolor flow cytometry that virus-induced and non- virus-induced asthma exacerbations show distinct activation patterns in peripheral blood T cells. Virus-induced ast...
  9. Allergen immunotherapy for allergic asthma: protocol for a systematic review.

    Clinical and Translational Allergy 6:5 (2015) PMID 26862389 PMCID PMC4746770

    The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for Allergic Asthma. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic asthma. We...
  10. Novel immunotherapy vaccine development.

    Current Opinion in Allergy and Clinical Immunology 14(6):557 (2014) PMID 25304230

    Allergen-specific immunotherapy is the only curative treatment for allergic diseases. In spite of the great progress in both vaccine development and the methods of allergen immunotherapy (AIT) in recent years, several key problems related to limited efficacy, side-effects, low patient adherence ...
  11. Ultra-Fast Hypoallergenic Birch Pollen Allergy Vaccine Allert Is Efficient and Safe: Results Of a Phase IIb Study

    Journal of Allergy and Clinical Immunology 133(2):AB290 (2014)

  12. Stanowisko Sekcji Immunoterapii Polskiego Towarzystwa Alergologicznego w sprawie prowadzenia alergenowo swoistej immunoterapii (AIT) u pacjentów zagrożonych wystąpieniem lub z rozpoznanymi chorobami na tle autoimmunizacji

    Alergologia Polska - Polish Journal of Allergology 2(1) (2014)

    Allergen immunotherapy (AIT) in patients with airborne allergy is crucial as the only therapeutic approach of causal treatment. For this reason, establishing contradictions for this treatment remain key issue in many patients. The currently understood AIT mechanisms unambiguously point...
  13. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development.

    Allergology International 62(4):425 (2013) PMID 24153333

    Allergen-specific immunotherapy (SIT) is the only available curative treatment of allergic diseases. Recent evidence provided a plausible explanation to its multiple mechanisms inducing both rapid desensitization and long-term allergen-specific immune tolerance, and suppression of allergic infla...
    PDF not found
  14. Human T regulatory cells: on the way to cognition.

    Archivum Immunologiae et Therapiae Experimentalis 61(3):229 (2013) PMID 23536196

    Forkhead box P3 (Foxp3)(+) T regulatory (Treg) cells are powerful controllers of the immune response and their role in the human immune system is indispensable. Since a number of revolutionary and very convincing results were brought to light, Foxp3 has unquestionably been thought to be the "mas...
  15. Current status of subcutaneous and sublingual immunotherapy with recombinant allergens.

    PMID 24912327

  16. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2.

    Journal of Allergy and Clinical Immunology 130(5):1153 (2012) PMID 22698521

    Early desensitization of FcεRI-bearing mast cells and basophils has been demonstrated in allergen-specific immunotherapy and drug desensitization. However, its mechanisms have not been elucidated in detail. Histamine is one of the main mediators released on FcεRI triggering of basophils and mast...
  17. Recombinant allergens: the present and the future.

    Human Vaccines & Immunotherapeutics 8(10):1534 (2012) PMID 23095874 PMCID PMC3660775

    Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including fo...
  18. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

    Clinical and Translational Allergy 2(1):20 (2012) PMID 23110958 PMCID PMC3514324

    Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European ...
  19. Research needs in allergy: an EAACI position paper, in collaboration with EFA.
    Nikolaos G Papadopoulos, Ioana Agache, Sevim Bavbek, Beatrice M Bilo, Fulvio Braido, Victoria Cardona, Adnan Custovic, Jan Demonchy, Pascal Demoly, Philippe Eigenmann, Jacques Gayraud, Clive Grattan, Enrico Heffler, Peter W Hellings, Marek Jutel, Edward Knol, Jan Lötvall, Antonella Muraro, Lars K Poulsen, Graham Roberts, Peter Schmid-Grendelmeier, Chrysanthi Skevaki, Massimo Triggiani, Ronald Vanree, Thomas Werfel, Breda Flood, Susanna Palkonen, Roberta Savli, Pia Allegri, Isabella Annesi-Maesano, Francesco Annunziato, Dario, Christian Apfelbacher, Miguel Blanca, Ewa Bogacka, Patrizia Bonadonna, Matteo Bonini, Onur Boyman, Knut Brockow, Peter Burney, Jeroen Buters, Indre Butiene, Moises Calderon, Lars Olaf Cardell, Jean-Christoph Caubet, Sevcan Celenk, Ewa Cichocka-Jarosz, Cemal Cingi, Mariana Couto, Nicolette Dejong, Stefano Del Giacco, Nikolaos Douladiris, Filippo Fassio, Jean-Luc Fauquert, Javier Fernandez, Montserrat Fernandez Rivas, Marta Ferrer, Carsten Flohr, James Gardner, Jon Genuneit, Philippe Gevaert, Anna Groblewska, Eckard Hamelmann, Hans Jürgen Hoffmann, Karin Hoffmann-Sommergruber, Lilit Hovhannisyan, Valérie Hox, Frode L Jahnsen, Omer Kalayci, Ayse Füsun Kalpaklioglu, Jörg Kleine-Tebbe, George Konstantinou, Marcin Kurowski, Susanne Lau, Roger Lauener, Antti Lauerma, Kirsty Logan, Antoine Magnan, Joanna Makowska, Heidi Makrinioti, Paraskevi Mangina, Felicia Manole, Adriano Mari, Angel Mazon, Clare Mills, Ervinç Mingomataj, Bodo Niggemann, Gunnar Nilsson, Markus Ollert, Liam O'Mahony, Serena O'Neil, Gianni Pala, Alberto Papi, Gianni Passalacqua, Michael Perkin, Oliver Pfaar, Constantinos Pitsios, Santiago Quirce, Ulrike Raap, Monika Raulf-Heimsoth, Claudio Rhyner, Paula Robson-Ansley, Rodrigo Rodrigues Alves, Zeljka Roje, Carmen Rondon, Odilija Rudzeviciene, Franziska Ruëff, Maia Rukhadze, Gabriele Rumi, Cansin Sackesen, Alexandra F Santos, Annalisa Santucci, Christian Scharf, Carsten Schmidt-Weber, Benno Schnyder, Jürgen Schwarze, Gianenrico Senna, Svetlana Sergejeva, Sven Seys, Andrea Siracusa, Isabel Skypala, Milena Sokolowska, Francois Spertini, Radoslaw Spiewak, Aline Sprikkelman, Gunter Sturm, Ines Swoboda, Ingrid Terreehorst, Elina Toskala, Claudia Traidl-Hoffmann, Carina Venter, Berber Vlieg-Boerstra, Paul Whitacker, Margitta Worm, Paraskevi Xepapadaki, and Cezmi Akdis

    Clinical and Translational Allergy 2(1):21 (2012) PMID 23121771 PMCID PMC3539924

    In less than half a century, allergy, originally perceived as a rare disease, has become a major public health threat, today affecting the lives of more than 60 million people in Europe, and probably close to one billion worldwide, thereby heavily impacting the budgets of public health systems....
  20. Immunological mechanisms of allergen-specific immunotherapy.

    Allergy 66(6):725 (2011) PMID 21466562

    The studies on the mechanisms of specific immunotherapy (SIT) point out its targets that decide on the efficacy of SIT and hence might be used for its further improvement. Several mechanisms have been proposed to explain the beneficial effects of immunotherapy. The knowledge of the mechanisms un...